Trevor Allred
Stock Analyst at Oppenheimer
(4.77)
# 552
Out of 4,382 analysts
42
Total ratings
82.8%
Success rate
56.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Reiterated: Buy | $210 | $108.67 | +93.25% | 7 | May 21, 2026 | |
| DNTH Dianthus Therapeutics | Rated: Hold | n/a | $80.51 | - | 7 | May 11, 2026 | |
| BBIO BridgeBio Pharma | Rated: Hold | n/a | $67.61 | - | 10 | May 11, 2026 | |
| TBPH Theravance Biopharma | Downgraded: Hold | $27 → $14 | $16.29 | -16.08% | 2 | Mar 5, 2026 | |
| INVA Innoviva | Downgraded: Buy | $35 | $22.52 | +55.42% | 3 | Feb 26, 2026 | |
| LGND Ligand Pharmaceuticals | Maintained: Buy | $250 → $275 | $237.00 | +16.03% | 9 | Nov 7, 2025 | |
| MBX MBX Biosciences | Maintained: Buy | $38 → $80 | $30.28 | +164.20% | 4 | Nov 7, 2025 |
Palvella Therapeutics
May 21, 2026
Reiterated: Buy
Price Target: $210
Current: $108.67
Upside: +93.25%
Dianthus Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $80.51
Upside: -
BridgeBio Pharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $67.61
Upside: -
Theravance Biopharma
Mar 5, 2026
Downgraded: Hold
Price Target: $27 → $14
Current: $16.29
Upside: -16.08%
Innoviva
Feb 26, 2026
Downgraded: Buy
Price Target: $35
Current: $22.52
Upside: +55.42%
Ligand Pharmaceuticals
Nov 7, 2025
Maintained: Buy
Price Target: $250 → $275
Current: $237.00
Upside: +16.03%
MBX Biosciences
Nov 7, 2025
Maintained: Buy
Price Target: $38 → $80
Current: $30.28
Upside: +164.20%